GLP-1 receptor agonists are revolutionizing treatments for weight-related illnesses like diabetes and obesity. Originally developed to mimic the GLP-1 hormone that regulates blood sugar and appetite, drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) have gained widespread acclaim for their efficacy and safety profile.

The global demand for these medications has surged, fueled by their proven ability to aid in weight loss and manage cardiovascular health. However, this demand has created challenges including supply shortages and the proliferation of unregulated and compounded alternatives.

In LegitScript’s recent webinar, we deep dive into the trends, risks, and compliance measures surrounding this booming market.
Here's what you need to know.

The Demand for GLP-1 Drugs: A Market on the Rise

With the rising rates of obesity and diabetes, GLP-1 drugs have become blockbuster products for pharmaceutical companies. Semaglutide and tirzepatide stand out for their effectiveness and minimal side effects—driving billions in sales.

Because of their success, supply shortages have limited access and given rise to alternative markets. Compounded versions of these drugs, which are produced without the same rigorous FDA approval process, have flooded the market. This increases the potential for safety and quality concerns.

Illicit Sales: A Growing Threat in the Digital Ecosystem

As demand outpaces supply bad actors have turned to e-commerce marketplaces, social media, and other peer-to-peer platforms to sell unauthorized and counterfeit versions of GLP-1 drugs.

Through our monitoring efforts, LegitScript saw a 200% increase in problematic GLP-1 ads in the first half of 2024 compared to 2023, underscoring the need for vigilance in the digital landscape.

In the webinar, we spotlight various tactics used by these online sellers including but not limited to:

• Misleading listings: To evade detection, sellers list their drugs under innocuous categories, such as collectibles or art supplies.
• Affiliate marketing networks: Influencers promote unapproved products through coded language and affiliate links—earning commissions on sales.
• Compounded products: Unregulated pharmacies sell compounded versions of GLP-1 drugs that may contain unsafe ingredients or incorrect dosages.
• These tactics are not just deceptive but dangerous, including instances of severe adverse effects and even fatalities.

Risks and Regulations in the GLP-1 Market

Regulators like the FDA have taken steps to address the risks associated with compounded and counterfeit GLP-1 drugs. However, enforcement challenges persist, particularly as sellers innovate new ways to bypass detection.

Common risks include:

• Tainted products: Counterfeit GLP-1 drugs have been found to contain toxins, bacteria, or undeclared ingredients.
• Misleading claims: Sellers often market non-drug products such as supplements as equivalent to FDA-approved drugs, creating confusion and legal risks.
• Improper dosage: Many compounded products lack proper labeling or require complex preparation, increasing the risk of overdose or misuse.

LegitScript’s Healthcare Certification: A Path to Safer Commerce

In the webinar, we discuss LegitScript’s Healthcare Certification program, which serves to build trust with prospective consumers while unlocking advertising and payment processing. The certification program helps pharmacies and telehealth companies navigate complex regulations, avoid inadvertent noncompliance, and build trust with consumers.

Major platforms like Google, Meta, Visa, and Mastercard recognize LegitScript’s certification as a gold standard for healthcare merchants—making it an essential asset for new and established organizations who want to advertise or process payments. Our robust vetting process ensures that only compliant merchants gain certification therefore fostering a safer ecosystem for all stakeholders.

Watch the Webinar to Get the Full Skinny

Do you want to explore these insights in more detail? The Skinny on New Weight Loss Drugs is packed with expert analysis, real-world case studies, and actionable tips to navigate the GLP-1 market.